Pharmacological Management of Idiopathic Pulmonary Fibrosis

التفاصيل البيبلوغرافية
العنوان: Pharmacological Management of Idiopathic Pulmonary Fibrosis
المؤلفون: Ladan Panahi, George Udeani, Andrew Scott Tenpas, Theresa Ofili, Elizabeth Marie Aguilar, Sarah Burchard, Alexandra Ruth Ritenour, April Jacob Chennat, Nehal Ahmed, Chairat Atphaisit, Crystal Chi, Jesus Cruz III, Monica D. Deleon, Samantha Lee, Zack Mayo, Mackenzie Mcbeth, Mariel Morales, Jennifer N. Nwosu, Kelly Palacios, Jaycob M. Pena, Nitza Vara
المصدر: Idiopathic Pulmonary Fibrosis
بيانات النشر: IntechOpen, 2021.
سنة النشر: 2021
مصطلحات موضوعية: respiratory system, humanities, respiratory tract diseases
الوصف: Idiopathic pulmonary fibrosis (IPF) is a common interstitial lung disease (ILD) caused by environmental exposures, infections, or traumatic injuries and subsequent epithelial damage. Since IPF is a progressively fatal disease without remission, treatment is both urgent and necessary. The two medications indicated solely for treatment include the tyrosine kinase inhibitor nintedanib (Ofev®) and the anti-fibrotic agent pirfenidone (Esbriet®). This chapter discusses in detail the current treatment options for clinical management of IPF, specifically the mentioned two pharmacotherapeutic agents that decrease physiological progression and likely improve progression-free survival. The chapter also discusses the evolution of drug therapy in IPF management and the drawbacks and limitations learned throughout historical trials and observational studies.
اللغة: English
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0070507ba6f34ad41be138db422064a4
https://mts.intechopen.com/articles/show/title/pharmacological-management-of-idiopathic-pulmonary-fibrosis
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....0070507ba6f34ad41be138db422064a4
قاعدة البيانات: OpenAIRE